Avita Medical Ltd
ASX:AVH ISIN:AU000000AVH4
News
Avita Medical Ltd. (ASX:AVH), (OTCMKTS:AVMXY) a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today announced that ReCell(R) will feature prominently during the scientific programme of the International Society for Burn Injuries' (ISBI) 17th Biennial Congress, in Sydney, Australia, October 12th to 16th.
Regenerative medicine company Avita Medical Ltd (ASX:AVH) (OTCMKTS:AVMXY) is pleased to welcome incoming Chairman, Lou Panaccio, who today has formally commenced his role.
HELICON GROUP LIMITED (ASX: HCG) announced today that the Chinese regulatory authority, the State Food and Drug Administration (SFDA) has formally accepted Helicon's dossier seeking marketing approval for the China market for ReCell(R).
Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 30 June 2007.
Clinical Cell Culture Limited (ASX: CCE) - 2nd Quarter Corporate Update - Mr Bob Atwill, CEO; Boardroomradio is pleased to announce that Clinical Cell Culture Limited (ASX: CCE) has published an audio file.
Clinical Cell Culture Ltd (ASX: CCE) today announced its intention to raise $10 million in additional capital, via a Share Purchase Plan (SPP), primarily to fund the further growth and commercialisation of the Company's lead product, ReCell (R) . The SPP is underwritten by Bell Potter Securities Limited.
Clinical Cell Culture Ltd (ASX: CCE) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL) for the supply of Trypsin, a key component of the Company's ReCell(R) tissue harvesting device.
Clinical Cell Culture Ltd (ASX: CCE) today announced that the TGA (Therapeutic Goods Administration) has completed its approval process and ReCell(R) has been placed on the Australian Register of Therapeutic Goods (ARTG).
Clinical Cell Culture Ltd (ASX: CCE) announced that it has appointed Bob Atwill as its new Chief Executive Officer and a Director of the Company. C3's Chief Financial Officer Andrew Cannon also joins the Board.
Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 31 March 2006.
130,875 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 51) (Last 30 Days: 165) (Since Published: 22727)